Literature DB >> 12107600

A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.

Giuseppe Boriani1, Mauro Biffi, Letizia Bacchi, Cristian Martignani, Romano Zannoli, Ghazwan S Butrous, Angelo Branzi.   

Abstract

OBJECTIVE: To assess the haemodynamic effects of short-term treatment with dofetilide in comparison with sotalol in patients with ischaemic heart disease.
METHODS: Twelve patients with ischaemic heart disease and sustained ventricular tachycardia were treated with dofetilide [500 microg twice daily (b.i.d.)] or sotalol (160 mg b.i.d., randomised sequence separated by wash-out period) for 3-5 days. Right-heart catheterisation was performed at baseline and at the end of each short-term treatment phase.
RESULTS: The main findings were a significant reduction in heart rate, mean systemic pressure and cardiac index (-13%) during treatment with sotalol. Conversely, cardiac index increased significantly during dofetilide (mean percentage change 11%) with no effect on heart rate and systemic blood pressure.
CONCLUSIONS: Oral dofetilide exerts favourable haemodynamic effects in comparison with D,L-sotalol following short-term oral treatment. In view of these observations, the use of dofetilide may be proposed also in patients with ventricular tachyarrhythmias associated with impaired left-ventricular function. Whether the haemodynamic differences between dofetilide and D,L-sotalol are the basis for differences in tolerability remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107600     DOI: 10.1007/s00228-002-0464-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  1 in total

1.  Dofetilide-induced long QT and torsades de pointes.

Authors:  Mehmet K Aktas; Abrar H Shah; Toshio Akiyama
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-07       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.